Glenn Gregory M 4

Accession 0001209191-21-070012

CIK 0001000694other

View on SEC.gov Company Profile

Filed

Dec 15, 7:00 PM ET

Accepted

Dec 16, 5:15 PM ET

Size

39.7 KB

Accession

0001209191-21-070012

Insider Transaction Report

Form 4

Period: 2021-12-14

NOVAVAX INCNVAX

Glenn Gregory M

Chief Scientific Officer

Transactions

Sale
Common Stock
2021-12-15$175.89/sh−67$11,785→ 6,222 total
Sale
Common Stock
2021-12-15$171.47/sh−254$43,553→ 6,765 total
Sale
Common Stock
2021-12-15$174.65/sh−137$23,927→ 6,289 total
Sale
Common Stock
2021-12-15$170.46/sh−213$36,309→ 7,019 total
Sale
Common Stock
2021-12-15$176.83/sh−223$39,432→ 5,999 total
Exercise/Conversion
Stock Option (Right to Buy)
2021-12-15−662→ 7,944 total
Exercise: $46.00Exp: 2028-12-13→ Common Stock (662 underlying)
Exercise/Conversion
Common Stock
2021-12-15$27.60/sh+1,024$28,262→ 6,687 total
Sale
Common Stock
2021-12-15$178.99/sh−103$18,436→ 5,896 total
Sale
Common Stock
2021-12-15$168.82/sh−117$19,752→ 7,232 total
Sale
Common Stock
2021-12-15$173.29/sh−91$15,770→ 6,426 total
Exercise/Conversion
Restricted Stock Units
2021-12-14−3,100→ 6,200 total
→ Common Stock (3,100 underlying)
Exercise/Conversion
Common Stock
2021-12-14+3,100→ 7,161 total
Exercise/Conversion
Common Stock
2021-12-15$46.00/sh+662$30,452→ 7,349 total
Sale
Common Stock
2021-12-15$180.62/sh−27$4,877→ 5,663 total
Tax Payment
Common Stock
2021-12-14$168.43/sh−1,498$252,308→ 5,663 total
Sale
Common Stock
2021-12-15$172.38/sh−248$42,750→ 6,517 total
Sale
Common Stock
2021-12-15$179.58/sh−206$36,993→ 5,690 total
Exercise/Conversion
Stock Option (Right to Buy)
2021-12-15−1,024→ 0 total
Exercise: $27.60Exp: 2027-12-15→ Common Stock (1,024 underlying)

Footnotes (16)

[F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.
[F10]The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $176.42 to $177.36, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
[F11]The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $178.29 to $179.26, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
[F12]The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $179.31 to $179.89, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
[F13]The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $180.47 to $180.81, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
[F14]The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan") vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the December 14, 2020 grant date, in each case subject to continued employment through such vesting date.
[F15]Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the December 15, 2017 grant date, and the remaining seventy-five percent (75%) of the shares vested in equal monthly installments over the following three (3) years subject to continued employment through such vesting date.
[F16]Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the December 13, 2018 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date.
[F2]The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
[F3]The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $168.61 to $169.27, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
[F4]The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $169.78 to $170.71, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
[F5]The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $170.94 to $171.93, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
[F6]The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $171.97 to $172.96, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
[F7]The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $172.97 to $173.79, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
[F8]The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $174.03 to $175.00, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
[F9]The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $175.31 to $176.29, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

NOVAVAX INC

CIK 0001000694

→

Entity typeother

Related Parties

filerCIK 0001342823

Filing Metadata

Form type: 4
Filed: Dec 15, 7:00 PM ET
Accepted: Dec 16, 5:15 PM ET
Size: 39.7 KB

View on SEC.gov